| |
Delivering
A World-Class Service
Encap is an innovative drug
delivery company serving the global pharmaceutical,
biotechnology and nutraceutical industries. We
offer customers access to our proprietary technology
platforms and manufacturing capability from early
drug development through our Collaborative
Partnership approach.
This partnership extends throughout the later
drug development phases to market launch and the
complete drug life-cycle. Encap’s encapsulation
technologies cover DuoCaps™,
LayerCaps™,
Abusolve™
and other technologies that provide unique solutions
for oral delivery where conventional methods have
fallen short. Our commercial-scale production
capacity of > 300 million capsules per annum
continues to expand. Encap operates to cGMP, holds
an MHRA Licence for Investigational Medicinal
Products (IMP’s) and is able to meet the
stringent quality requirements set by the world’s
most demanding regulatory bodies
Located within modern, purpose-built R&D and
production facilities close to Edinburgh, we are
able to draw upon the extensive scientific and
engineering talent from some of the World’s
leading University’s located in Scotland
Many international companies already trust Encap
to help them get their new products to market
expediently, safely and cost-efficiently. We offer
fully integrated analytical development services,
clinical trial manufacturing, packaging and supply
management, project management, technology transfer
and contract manufacture.
| Our Mission
is to provide our customers with unrivalled
drug delivery solutions supported by a dedicated
quality manufacturing capability to meet
their product needs from early development
and throughout the product life-cycle. |
 |
Encap
holds a Medicines and Healthcare Product
Regulatory Agency Licence for Investigational
Medicinal Products (IMP’s) and adheres
to all standards as set out under European
cGMP legislation |
 |
Encap is able
to meet the stringent quality requirements
set by the world’s most demanding
regulatory bodies and is currently in preparation
for an FDA inspection for one of its largest
pharmaceutical products |
|
|
